title: High-sensitivity C-reactive Protein and Tumor Necrosis Factor Alpha in Pseudoexfoliation Syndrome.
abstract: OBJECTIVE
  The purpose of the present study was to determine the alterations in high-sensitivity C-reactive protein and Tumor Necrosis factor alpha levels in the blood serum of pseudoexfoliation syndrome cases (a disease with similar risk factors as systemic endothelial dysfunction diseases) and to compare the results with healthy individuals.
  
  
  METHODS
  High-sensitivity C-reactive protein and Tumor Necrosis factor alpha levels were determined in 30 cases with pseudoexfoliation syndrome and in 30 control patients of the same age and sex, by enzyme-linked immunosorbent assay.
  
  
  RESULTS
  The levels of high- sensitivity C-reactive protein and Tumor Necrosis factor alpha in the blood serum of patients with pseudoexfoliation syndrome (3.95±0.88 mg/l, 3.32±0.99 pg/ml, respectively) were significantly higher than in the control group (2.51±0.79mg/l, 0.43±0.15 pg/ml, respectively) p=0.001, p=0.002.
  
  
  CONCLUSIONS
  The results suggest that increased levels of high- sensitivity C-reactive protein and Tumor Necrosis factor alpha, as markers of inflammation and peripheral endothelial dysfunction in pseudoexfoliation syndrome, may be risk factors for systemic and ocular manifestations of pseudoexfoliation syndrome.
authors: Department of Ophthalmology, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Rana
authors: R
authors: Sorkhabi
authors: Amir
authors: A
authors: Ghorbanihaghjo
authors: Mohamadhossein
authors: M
authors: Ahoor
authors: Mehriar
authors: M
authors: Nahaei
authors: Nadereh
authors: N
authors: Rashtchizadeh
keywords: High sensitivity C-reactive protein; Pseudoexfoliation syndrome; Tumor necrosis factor alpha
references: Oman Med J. 2012 Jul;27(4):285-90
references: 23071879
references: Br J Ophthalmol. 2006 May;90(5):563-7
references: 16488931
references: Scand J Clin Lab Invest. 2006;66(1):45-54
references: 16464786
references: Invest Ophthalmol Vis Sci. 2010 Feb;51(2):903-6
references: 19737888
references: J Neurosci. 2006 Dec 6;26(49):12633-41
references: 17151265
references: J Glaucoma. 2007 May;16(3):320-3
references: 17438427
references: Graefes Arch Clin Exp Ophthalmol. 2004 Sep;242(9):749-54
references: 15052489
references: Eye (Lond). 2002 Mar;16(2):163-70
references: 11988817
references: Circulation. 2000 Oct 31;102(18):2165-8
references: 11056086
references: Mol Vis. 2007 Sep 05;13:1573-9
references: 17893658
references: Graefes Arch Clin Exp Ophthalmol. 2005 Jul;243(7):677-83
references: 15688159
references: Graefes Arch Clin Exp Ophthalmol. 2006 Mar;244(3):316-21
references: 16133017
references: Curr Opin Cardiol. 2003 Nov;18(6):471-8
references: 14597888
references: J Glaucoma. 2007 Mar;16(2):234-9
references: 17473737
references: World J Gastroenterol. 2007 Jun 7;13(21):2960-6
references: 17589947
references: Mol Vis. 2011 Jan 07;17:41-6
references: 21245957
references: Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1117-25
references: 12601038
references: Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3246-52
references: 17591895
references: Mediators Inflamm. 2007;2007:92196
references: 17641733
references: Prog Retin Eye Res. 2003 May;22(3):253-75
references: 12852486
references: Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13352-6
references: 15340151
references: Am J Ophthalmol. 2004 Jul;138(1):162-4
references: 15234308
references: Am J Ophthalmol. 2006 May;141(5):921-937
references: 16678509
references: Acta Ophthalmol. 2009 Mar;87(2):216-21
references: 18577187
references: Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4359-67
references: 15557444
references: J Biol Chem. 2004 Jul 30;279(31):32869-81
references: 15155767
references: Exp Eye Res. 2005 Aug;81(2):207-17
references: 16080915
references: J Glaucoma. 2010 Aug;19(6):373-6
references: 19855290
references: Int Heart J. 2006 Jan;47(1):77-84
references: 16479043
references: Surv Ophthalmol. 2001 Jan-Feb;45(4):265-315
references: 11166342